Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
NCT06006273Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eribulin in solid tumor (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
eribulin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06006273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006273.